Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Christie

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
The Lancet. Oncology|November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialJames W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancerDavid S Lamb, James W Denham, Hedy Mameghan, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 28, 2008
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trialAnne Capp, Mario Inostroza-Ponta, Dana Bill, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2025
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized TrialJarad M Martin, Tanya Burgess, Brett McClelland, et al.
The Lancet. Oncology|August 5, 2006
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer NetworkAurelius Omlin, Maurizio Amichetti, David Azria, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 8, 2005
Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivationDavid Christie, James Denham, Allison Steigler, et al.
BMJ Open|August 23, 2019
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocolJarad Martin, Paul Keall, Shankar Siva, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR TrialDavid Joseph, James W Denham, Allison Steigler, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
The Lancet. Oncology|November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialJames W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancerDavid S Lamb, James W Denham, Hedy Mameghan, et al.
Leukemia & Lymphoma|December 4, 2013
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)Silvia Govi, David Christie, Silvia Mappa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 28, 2008
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trialAnne Capp, Mario Inostroza-Ponta, Dana Bill, et al.
International Journal of Radiation Oncology, Biology, Physics|September 30, 2025
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized TrialJarad M Martin, Tanya Burgess, Brett McClelland, et al.
The Lancet. Oncology|August 5, 2006
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer NetworkAurelius Omlin, Maurizio Amichetti, David Azria, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 8, 2005
Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivationDavid Christie, James Denham, Allison Steigler, et al.
BMJ Open|August 23, 2019
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocolJarad Martin, Paul Keall, Shankar Siva, et al.
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR TrialDavid Joseph, James W Denham, Allison Steigler, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Pageof 6